Atrial fibrillation screening for people with higher-than-median NT-proBNP in Tromsø
Official title: Atrial Fibrillation and Long Term ECG Monitoring of Heart Rhythm in the Tromsø Study
Run by University Hospital of North Norway · NCT07343895 · Data updated 2026-11-12
This will test whether giving 7-day wearable ECG monitoring to people aged 40+ with NT-proBNP above the median can find atrial fibrillation and reduce ischemic stroke and vascular deaths compared with no long-term monitoring.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | University Hospital of North Norway Academic / other |
| Locations | 2 sites (Tromsø and 1 other locations) |
| Status | Recruiting |
| Started | October 24, 2025 |
| Main results expected | March 1, 2032 |
| Study ends | March 1, 2035 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07343895 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40 years or older with NT-proBNP above the population median, no known atrial fibrillation, not on anticoagulation, and willing to provide informed consent are ideal candidates.
✕Probably not a fit
People with known AF, those already taking anticoagulants, those with pacemaker/CRT devices, or those without a smartphone (or with NT-proBNP at or below the median) are not eligible and unlikely to benefit from this screening strategy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized sub-study within the Tromsø population cohort will enroll 4,000 participants with NT-proBNP above the median and no prior AF or anticoagulation, randomizing 2,000 to 7-day continuous ECG monitoring with the ECG247 patch and AI-based analysis and 2,000 to usual care without long-term monitoring. Participants in whom AF is detected will be offered anticoagulation according to current international guidelines. The primary comparison is incident ischemic stroke and cardiovascular death between the screened and unscreened groups over follow-up. Extensive baseline data from the Tromsø Study will allow analyses of associations with echocardiographic measures, brain MRI changes, cognition, and quality of life.
Why it matters
Potential benefit: If successful, this approach could detect otherwise-hidden AF earlier and lower the risk of ischemic stroke and vascular death by directing appropriate anticoagulation.
How similar studies have gone: Prolonged ECG monitoring is known to increase AF detection in other studies, but whether screening reduces stroke is still uncertain and using NT-proBNP as a prescreening step is a relatively new, less-tested approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥40 years * NT-proBNP\> median level * Informed consent for participation Exclusion Criteria: * History of AF (self-reported) * Use of anticoagulation therapy * Pacemaker/CRT device * No available smart phone
Where it's running
-
Uit The Arctic University of Norway
Tromsø, Norway Recruiting -
University Hospital of North Norway Health Trust
Tromsø, Norway Recruiting
Study contacts
- Study coordinator: Agnethe Eltoft, MD, PhD
- Email: agnethe.eltoft@unn.no
- Phone: +4797193417
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cardiovascular risk in people with Crohn's disease and ulcerative colitis
This study tests whether people with inflammatory bowel disease have different heart-attack or stroke risk over two years compared with matched controls.
-
Integrated care for older patients with atrial fibrillation
This study is testing a new team-based care approach for older patients with atrial fibrillation and other health issues to see if it helps them manage their condition better than regular care.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
-
Photoplethysmography-based algorithm to detect atrial fibrillation in heart failure patients
A wearable-based, AI-powered test using PPG signals to see if a patient with heart failure has atrial fibrillation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.